Navigating the FDA: Inside the Mind of a Former Reviewer

Welcome back to the blog extension of our ongoing podcast series! If you are a medical device innovator, engineer, or entrepreneur, you already know that the journey from a brilliant idea on a whiteboard to an actual device helping patients in a clinical setting is a monumental undertaking. One of the most critical checkpoints in that journey is dealing with the United States Food and Drug Administration. For many, the FDA can feel like a mysterious, monolithic entity that speaks in a language all its own. But what if you could pull back the curtain and look at the regulatory process through the eyes of the very people who review your submissions?

In this post, we are going to dive deep into the mechanics of FDA regulatory strategy, drawing inspiration and hard-earned wisdom from our recent interview with Dr. Allison Komiyama, CEO and Founder of Bluestocking Health. Allison brings a rare and invaluable perspective to the table: she has sat on both sides of the table. Having served as an FDA reviewer in the Center for Devices and Radiological Health and subsequently spending decades helping companies navigate the pre-submission and premarket pathways, she understands the inner workings of regulatory agencies better than almost anyone. Whether you are prepping your very first 510(k) or managing a complex portfolio of life-changing technologies, understanding the FDA mindset is your greatest asset.

From Reviewer to Consultant: The Journey of Allison Komiyama

To truly understand how to work with the FDA, it helps to understand how regulators think, and that mindset is largely shaped by their training, their mission, and their daily environment. Allison Komiyama’s journey into the regulatory space is a fascinating testament to the intersection of rigorous hard science and practical policy. With a degree in Molecular and Cell Biology from the University of California, Berkeley, and a doctorate in Neuroscience from Stanford University, Allison started her career deeply entrenched in the world of basic science and academic research.

However, she quickly realized that she wanted her work to have a more direct, tangible impact on human health. This desire led her to the FDA, where she served as a reviewer in the Center for Devices and Radiological Health (CDRH). Working inside the agency gave her a front-row seat to the staggering variety of medical technologies being developed around the world, as well as a clear view of the common pitfalls that inventors fall into. Reviewers are tasked with a heavy responsibility: protecting public health while ensuring that safe and effective technologies can reach the market efficiently. They are scientists and engineers who rely heavily on clear data, sound logic, and adherence to established regulatory frameworks.

After her time inside the agency, Allison transitioned to the consulting side, founding AcKnowledge Regulatory Strategies in 2014 and later launching Bluestocking Health in 2025. Over her seventeen-year career in the regulatory space, she has been involved in hundreds of pre-submissions and premarket submissions across a vast array of medical device categories. This evolution from academic researcher to federal reviewer to private consultant gives her a 360-degree view of the MedTech ecosystem. Her story teaches us that the FDA is not an adversary to be conquered, but rather a scientific partner whose language you must learn to speak fluently.

Demystifying the FDA Pre-Submission Process

One of the most powerful tools available to medical device developers—and yet one of the most frequently underutilized—is the FDA Pre-Submission program, often referred to as the Pre-Sub. Many early-stage companies are terrified of interacting with the agency too early. They harbor a persistent fear that if they talk to the FDA before their device is completely finalized, the agency will flag them, shut them down, or put them in a bureaucratic box from which they can never escape. According to Allison Komiyama, this fear is entirely unfounded and deeply counterproductive.

From a reviewer’s perspective, getting feedback early is a win-win. Reviewers genuinely want companies to succeed, provided the technology is safe and effective. When you submit a Pre-Sub, you are essentially opening a formal line of communication to ask specific, targeted questions about your testing strategy, your intended use, your clinical protocol, or your choice of predicate devices. Instead of guessing what the FDA wants to see and spending hundreds of thousands of dollars on the wrong kinds of biocompatibility or bench testing, a Pre-Sub allows you to get direct validation from the review division before you pull the trigger on your pivotal studies.

To make the most of the pre-submission process, you must treat it with the same professional rigor as your actual marketing application. Do not show up to a Pre-Sub meeting with a vague concept and a handful of hand-drawn sketches. Come prepared with a well-defined device description, a clear understanding of your proposed indication for use, and a tightly focused list of questions. The more specific and well-reasoned your questions are, the more actionable and useful the FDA’s feedback will be. Think of the Pre-Sub as a collaborative rehearsal for your actual review—it gives you a chance to address potential concerns, align on expectations, and build a positive working relationship with the agency officials who will eventually evaluate your final submission.

Best Practices for Premarket Submissions

Once you have navigated the pre-submission phase and executed your testing protocols, the time comes to compile and submit your premarket application—whether that is a 510(k), a De Novo classification request, or a Premarket Approval (PMA) application. This is the moment where many companies stumble, not necessarily because their technology is flawed, but because their submission package is poorly organized, difficult to navigate, or lacking in essential detail. Reviewers are remarkably busy people managing heavy caseloads; if your submission is a chaotic maze of disjointed documents, you are making their job unnecessarily difficult.

Allison emphasizes that clarity, consistency, and completeness are the cornerstones of a successful premarket submission. Every claim you make in your labeling must be explicitly backed up by the data contained in your testing reports. If there is a disconnect between your bench testing, your animal studies, or your clinical data and the claims you are making about what the device can do, the reviewer is going to issue an Additional Information (AI) request, which will bring your review clock to a screeching halt and delay your path to market.

Best practices for premarket submissions also include proactive risk management. Your submission should clearly demonstrate that you have anticipated potential failure modes, evaluated safety risks, and implemented appropriate mitigations. Furthermore, formatting matters immensely. Use clear headings, comprehensive tables of contents, and cross-references that allow a reviewer to easily trace a requirement to its corresponding evidence. When you make it easy for a reviewer to find what they need and understand your scientific rationale, you dramatically increase the likelihood of a smooth, efficient review process.

The Critical Role of Clinical Evidence in MedTech

At the heart of every regulatory discussion is a fundamental question: Where is the clinical evidence? In the medical device industry, great engineering and sleek industrial design are never enough on their own. You can build the most elegant, technologically advanced device in the world, but if you cannot prove through rigorous clinical data that it performs safely and effectively in human patients, it will never see the light of day in a commercial hospital or clinic.

The type and amount of clinical evidence required can vary wildly depending on the regulatory classification and novelty of your device. For a traditional 510(k) submission, you may be able to rely on substantial equivalence to a legally marketed predicate device, utilizing existing literature, bench testing, and perhaps some targeted clinical data. However, for novel technologies entering via the De Novo pathway or high-risk devices requiring a PMA, robust, prospective clinical trials are often mandatory.

Designing these clinical trials requires a delicate balance between commercial ambitions and statistical rigor. You need to work with biostatisticians and clinical research experts to ensure your endpoints are clinically meaningful and statistically defensible. Moreover, you must consider diversity and representation in your clinical cohorts to ensure the device performs safely across the broader patient populations who will ultimately use it. Allison’s background in neuroscience and molecular biology gives her a deep appreciation for this scientific rigor. She notes that building a strong clinical narrative is not just about checking a regulatory box—it is about generating genuine scientific proof that your technology delivers on its promises and truly improves patient outcomes.

Communicating the Value of Healthcare Innovation

Navigating the regulatory landscape and securing FDA clearance is a monumental milestone, but it is not the final destination. Once a medical device is cleared or approved, the challenge shifts from regulatory compliance to commercial adoption. In today’s complex healthcare ecosystem, simply having a great device is not enough; you must be able to effectively communicate the value of your innovation to a wide array of stakeholders, including hospital administrators, physicians, payers, and patients.

This is a core mission behind Allison’s latest venture, Bluestocking Health, which she founded in 2025. Bluestocking Health was created to foster deeper conversations around medical devices, science, clinical evidence, and healthcare. Too often, innovators struggle to translate complex technical data and regulatory jargon into a compelling value proposition that resonates with decision-makers. Hospital value analysis committees do not just want to know how a device works on a cellular level; they want to know how it impacts clinical workflows, reduces readmission rates, improves patient satisfaction, and fits into existing reimbursement structures.

Communicating value requires a strategic narrative that bridges the gap between hard science and human impact. You must be able to tell the story of your device in a way that connects regulatory success to clinical excellence and economic viability. By positioning your technology clearly within the broader context of modern healthcare, you can accelerate adoption, secure favorable reimbursement, and ultimately ensure that your life-changing innovation reaches the patients who need it most.

Conclusion and Key Takeaways for Medical Device Companies

Bringing a medical device to market is an extraordinarily complex journey that requires a rare combination of scientific brilliance, strategic foresight, and unwavering persistence. As we have explored in this post—and as our guest Allison Komiyama so eloquently shares—success in the MedTech space is deeply tied to how well you understand and collaborate with regulatory bodies like the FDA. By viewing regulators as scientific partners rather than adversaries, engaging early through the pre-submission process, maintaining rigorous standards for your clinical data, and mastering the art of communicating your value, you can transform the regulatory hurdle into a competitive advantage.

To dive even deeper into these strategies, hear firsthand stories from Allison’s impressive seventeen-year career, and gain actionable insights into the intersection of science, regulation, and medical technology, you won't want to miss our full conversation. Listen to the complete episode by visiting Allison Komiyama, CEO and Founder at Bluestocking Health, LLC. Equip yourself with the insider knowledge you need to bring your innovations to market faster and make a lasting impact on human health!